 |
|
An Open-label Adrenal Suppression Study of 0.1% Fluocinonide Cream in Pediatric Patients With Atopic Dermatitis
Joel Schlessinger, MD;
Bruce Miller, MD;
Richard D. Gilbert, PhD;
R. Todd Plott, MD;
Arch Dermatol. 2006;142:1568-1572.
Objective To assess the potential of a superhigh-potency 0.1% fluocinonide cream to suppress the hypothalamic-pituitary-adrenal (HPA) axis in pediatric patients with atopic dermatitis.
Design A multicenter, multiple-dose, open-label safety study in 4 age cohorts with 0.1% fluocinonide cream applied once or twice daily for 2 weeks.
Setting Clinical outpatient setting.
Patients Patients with moderate to severe atopic dermatitis with 20% or more of the body surface area involved were included in the study. Each cohort began only after evaluation of the preceding cohort: ages 12 to younger than 18 years (cohort 1); 6 to younger than 12 years (cohort 2); 2 to younger than 6 years (cohort 3); and 3 months to younger than 2 years (cohort 4).
Main Outcome Measures Assessment of HPA axis suppression, local and systemic adverse events, and change in disease status from baseline.
Results Suppression of the HPA axis was not observed in any patient treated once daily for the 2 youngest cohorts. Suppression was observed in 1 (7%) of 15 and 2 (12%) of 16 patients in the fluocinonide twice-daily group in cohorts 1 and 2, respectively. In all 4 cohorts, more than 90% of patients in the fluocinonide once-daily and twice-daily groups showed improvement in their disease status.
Conclusions Once-daily treatment with 0.1% fluocinonide cream for 2 weeks does not result in HPA axis suppression under the conditions of this study. Once-daily applications provided similar or better efficacy as twice-daily applications with a lower risk of HPA axis suppression. The frequency of HPA axis suppression is no greater in younger children than in older children.
Trial Registration isrctn.org Identifier: ISRCTN71227633
Author Affiliations: Skin Specialists PC, Advanced Skin Research Center, Omaha, Neb (Dr Schlessinger); Oregon Medical Research Center Inc, Portland (Dr Miller); TKL Research Inc, Paramus, NJ (Dr Gilbert); and Medicis Pharmaceutical Corp, Scottsdale, Ariz (Dr Plott).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Management of Atopic Dermatitis in the Pediatric Population
Krakowski et al.
Pediatrics 2008;122:812-824.
ABSTRACT
| FULL TEXT
Suppression of the HPA Axis in Pediatric Patients With Atopic Dermatitis
Ishay et al.
Arch Dermatol 2007;143:1449-1450.
FULL TEXT
Established corticosteroid creams should be applied only once daily in patients with atopic eczema
Williams
BMJ 2007;334:1272-1272.
FULL TEXT
|
